dextroamphetamine + scopolamine

Dextroamphetamine + scopolamine is an oral combination of two small molecule drugs—dextroamphetamine, a central nervous system stimulant, and scopolamine, an anticholinergic agent. This combination has been studied primarily for the prevention and management of severe motion sickness, especially in operational environments such as spaceflight and aviation[1][3][5][7][9]. Dextroamphetamine increases synaptic concentrations of dopamine and norepinephrine by inhibiting their reuptake and promoting their release in the brain[8]. Scopolamine acts as a competitive antagonist at muscarinic acetylcholine receptors, thereby reducing parasympathetic activity and suppressing nausea/vomiting associated with motion sickness[2]. The rationale for combining these agents is to counteract the sedative/cognitive-impairing effects of scopolamine with the stimulating properties of dextroamphetamine while enhancing anti-motion sickness efficacy. This combination is not FDA-approved for any indication but has been used off-label in specialized settings such as NASA's space program[3][5][9].

Other names

scopolamine-dextroamphetamineSMS medication